DOPA-RESPONSIVE DYSTONIA

 

DOPA-RESPONSIVE DYSTONIA

 

DEFINITION:

A slowly-progressive movement disorder characterized by dystonia and parkinsonian features.

EPIDEMIOLOGY:

  • prevalence: 0.5/1,000,000
  • age of onset:
    • usually from 4-8 yrs; may present in infancy
  • risk factors:
    • familial - autosomal dominant with sex-related reduced pene-trance
    • chrom.#: 14q
    • gene: ?
  • F > M (2.5:1)
  • occurs worldwide with no increased prevalence in any ethnic group

PATHOGENESIS:

1. Background

  • also called Segawa Disease
  • the Dopa-Responsive Dystonia (DRD) gene has been mapped to chromosome 14q (Nygaard et al., Nature Genetics 5:386-391, 1993)
  • all three forms of inherited dystonia have had their disease locus genetically mapped
    • Idiopathic Torsion Dystonia - 9q32-34
    • Dopa-Responsive Dystonia - 14q
    • X-linked Dystonia-Parkinsonism - Xq21

2. Genetic Defect

  • genetic defect -> deficiency of striatal dopamine -> dystonia with parkinsonian features
  • the DRD gene may be responsible for the normal development or maintenance of the striatal dopaminergic system and a defect in the gene may result in a:
    • reduced number of dopaminergic nerve terminals occurring during development
    • excessive reduction (pruning) of these terminals occurring during post-natal development

CLINICAL FEATURES:

1. Dystonic Manifestations

  • see "Dystonic Disorders"
  • usually presents as a gait disturbance with leg dystonia
  • diurnal fluctuations
    • gait disturbance or abnormal lower extremity posture tend to occur late in the afternoon
  • dystonia exacerbated by movement and exercise
  • associated with parkinsonian features
    • cogwheel rigidity, masklike facies, and bradykinesia
  • associated with postural or intention tremor in 50% of patients
  • may find family history of dopa-responsive dystonia, variable degrees if dystonia, and parkinsonism

INVESTIGATIONS:

1. Serum

  • low biopterin levels (a cofactor for tyrosine hydroxylase - the rate limiting step in dopamine production)

2. Cerebral Spinal Fluid

  • reduced levels of homovanillic acid (a dopamine metabolite)

3. Imaging Studies

  • 1. PET

    • abnormal dopamine metabolism
      • in striatal dopa decarboxylation, uptake, and storage
  • MANAGEMENT:

  • 1. Carbidopa-Levodopa (Sinemet)

    • dramatic improvement within several days of initiation of therapy
    • when used in combination with carbidopa, may decrease dosage requirements (50mg/day) of levodopa
    • long-term therapy needed as symptoms return when drug discon-tinued
    • side-effects
      • dyskinesia
        • worse with increased severity and duration of disease
        • alleviated with removeal of levodopa
  •  

     

    Pediatric Database - DOPA-RESPONSIVE DYSTONIA

    Pediatric Organization - Pedbase [at] Gmail.com